Anzeige
Mehr »
Mittwoch, 24.06.2026 - Börsentäglich über 12.000 News
Schuldenfrei, 1,5 Mio. Unzen Gold und Produktion ab 2027: Vor dem Ausbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XEH4 | ISIN: FR0011716265 | Ticker-Symbol: 74C
Stuttgart
23.06.26 | 21:57
1,850 Euro
-0,43 % -0,008
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CROSSJECT SA Chart 1 Jahr
5-Tage-Chart
CROSSJECT SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,8741,90023.06.
1,8521,91023.06.

Aktuelle News zur CROSSJECT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CROSSJECT Aktie jetzt für 0€ handeln
22.05.CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million293Provides immediate new financing to support the Company's next strategic milestones Strengthens shareholders' equity and improves the Company's financial structure Supports the continuation of ZEPIZURE®...
► Artikel lesen
25.03.CROSSJECT appoints Lionel Seltz as Chief Financial Officer300DIJON, France - 25 mars 2026 (06.00 PM CET) - CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO®...
► Artikel lesen
25.03.CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory551DIJON, France - 25 March 2026 (07:20 AM CET) - CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary...
► Artikel lesen
02.02.CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)788CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France - February 2, 2026 (7:15 a.m. CET) - CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty...
► Artikel lesen
14.11.25CROSSJECT completes €5 million financing with Vatel Capital678Press release CROSSJECT completes €5 million financing with Vatel Capital DIJON, France - November 14th, 2025 (8.30 PM CET) - CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals...
► Artikel lesen
24.09.25CROSSJECT presents its financial results and key highlights for the first half of 2025375Press release CROSSJECT presents its financial results and key highlights for the first half of 2025 Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the...
► Artikel lesen
22.09.25CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE (ZENEO Midazolam)316Press release CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) DIJON, France - September 22, 2025 (7.30 AM...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1